Pharmaceutical Technology52m
Sanofi in talks to sell stake in consumer healthcare unit to CD&R
Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), regarding the potential sale of a 50% controlling ...
FDA approves Pfizer’s HYMPAVZI to treat haemophilia
HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.
Pharmabiz2h
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors
Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 14:10 Hrs [IST] Pfizer ...
Daily2h
Pfizer Hemophilia drug Hympavzi Receives USFDA Approval
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...
pharmaphorum5h
Pfizer rounds out haemophilia portfolio with FDA approval
The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...
The Financial Express5h
USFDA gives nod to Pfizer’s drug therapy for patients with Hemophilia
The FDA granted the approval of Hympavzi to Pfizer Inc.